title: Frequent disease progression and early recurrence in patients with familial ovarian cancer primarily treated with paclitaxel and cis- or carboplatin (preliminary report).
abstract: OBJECTIVE
  To evaluate frequencies of early disease progressions and recurrences in patients with familial vs sporadic ovarian cancers following primary paclitaxel/cis- or carboplatin chemotherapy.
  
  
  METHODS
  The frequencies of disease progression up to six months following primary paclitaxel/cis- or carboplatin and of early disease recurrences were analysed in 18 Stage III patients with familial ovarian cancers, both carriers and non-carriers of 5382 insC BRCA1 mutation, and in 35 patients with Stage III sporadic ovarian tumors.
  
  
  RESULTS
  Progressive disease within first six months following chemotherapy developed in 5/18 patients with familial cancers vs. 5/35 patients with sporadic tumors. Early disease recurrences (up to 6 months after treatment) occurred in 3/18 patients with familial vs. 2/35 patients with sporadic tumors. Recurrences after 7-12 months following treatment occurred, respectively, in 3/13 and 3/31 patients from these groups.
  
  
  CONCLUSIONS
  The results of this preliminary report may suggest that patients with familial ovarian tumors respond less favourably to paclitaxel/cis- or carboplatin treatment than patients with sporadic ovarian tumors. These findings should be however confirmed in a prospective study on a larger group of patients.
authors.affiliation: Genetic Counselling Unit, Great Poland Cancer Center, Poznań, Poland.
authors.forename: A
authors.initials: A
authors.lastname: Wojciechowska-Lacka
authors.forename: J
authors.initials: J
authors.lastname: Markowska
authors.forename: E
authors.initials: E
authors.lastname: Skasko
authors.forename: A
authors.initials: A
authors.lastname: Kruczek
authors.forename: J
authors.initials: J
authors.lastname: Steffen
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001707:Biopsy, Needle; D016190:Carboplatin / Q000008:administration & dosage; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D019398:Genes, BRCA1; D020022:Genetic Predisposition to Disease; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000453:epidemiology*; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage; D011044:Poland; D011446:Prospective Studies; D012307:Risk Factors; D012494:Sampling Studies; D016019:Survival Analysis; D017211:Treatment Failure
chemical_list: D016190:Carboplatin; D017239:Paclitaxel